DEPRESSIVE DISORDERS MARKET: OVERVIEW
As per Roots Analysis, the global depressive disorders market is anticipated to grow at a lucrative CAGR during the forecast period.
The market sizing and opportunity analysis has been segmented across the following parameters:
Type of Depression
- Major Depression Disorder
- Bipolar Disorder
- Postpartum Depression
- Treatment-Resistant Depression
- Others
Type of Molecule
Type of Therapy
- Monotherapy
- Adjunctive Therapy
- Combination Therapy
- Sequential Therapy
Route of Administration
- Oral
- Parenteral
- Nasal
- Transdermal
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
DEPRESSIVE DISORDERS MARKET: GROWTH AND TRENDS
Depression is a mental health disorder characterized by a constant feeling of sadness and lack of interest in external stimuli. Notably, this chronic condition is considered among the leading causes of mental disability worldwide. In fact, it is worth mentioning that, globally more than 300 million people of all age groups suffer from depression. Moreover, depressive disorders are estimated to cause an economic burden of approximately USD 210 billion in the US, annually. Despite its widespread occurrence and substantial impact, less than 50% of people with this condition receive treatment in high-income countries, and this number drops to less than 10% in low-income countries. As a result, a large number of branded drugs and over 150 generic products have been approved by the FDA to treat depression among patients. Despite the availability of generics and other branded drugs, patients have voiced the need for better antidepressants.

Consequently, the rising demand for better antidepressants has led stakeholders to undertake various initiatives to develop interventions and drug / therapy candidates with novel mechanism of action to treat depression. Recently, stakeholders have begun relying more on personalized approaches, incorporating new therapies, such as Transcranial Direct Current Stimulation (tDCS) and ketamine, and exploring the link between the gut microbiome and depression.
DEPRESSIVE DISORDERS MARKET: KEY INSIGHTS
The report delves into the current state of the global depressive disorders market and identifies potential growth opportunities within industry. Some key findings from the report include:
- Over the past few years, the depressive disorders market has witnessed multiple clinical stage drug failures; amongst the various reported reasons, inability to achieve specific clinical endpoints was the most common.

- The current market landscape is fragmented, featuring small companies and established pharma giants, which are engaged in the development of over 65 drug candidates for treating different forms of depression.
- Several molecules in the development pipeline are in the late stages of clinical development; majority of the drugs are monotherapies and designed for delivery via oral route.
- With several marketed drugs and a healthy clinical pipeline, the opportunity in this domain is expected to evolve steadily as more product candidates get approved.
- Majority of the lead molecules are being evaluated as monotherapies; however, developers are also evaluating certain drugs as an adjunctive or combination therapy.
- Currently, the depressive drugs pipeline is dominated by orally administrable drugs; however, other routes of administration, such as nasal and transdermal, are also being investigated.
- Although clinical studies are registered across various geographies, maximum number of trials are being conducted in North America; over 70% of clinical trials are evaluating drugs in Phase II / Phase III.
- In lieu of the evolving product landscape, drug developers are putting in significant efforts to ensure that their candidates are clinically and commercially competent.
- A substantial proportion of partnerships in this domain are focused on digital therapeutics initiatives; with over USD 3 billion investments since 2010, companies have received active support from investors.
- Companies, such as Janssen Pharmaceutical, Lundbeck, Vistagen Therapeutics, Takeda Pharmaceutical and Otsuka Pharmaceutical, have signed multiple deals related to depressive disorders; majority of the aforementioned agreements were signed for R&D purpose.
- Around 60% of the total amount was invested in the last three years. Specifically, till March alone, companies engaged in this domain had collectively raised USD 650 million. Overall, a sum of USD 2.8 billion was raised by various industry stakeholders through secondary offerings.
- Stakeholders are exploring diverse commercialization strategies across different stages of a product's launch cycle; with drugs nearing patent expiry, developers are expected to adopt lifecycle management approaches.

Example Players in the Depressive Disorders Market
- AbbVie
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- GSK
- H. Lundbeck
- Johnson & Johnson
- Merck
- Pfizer
- Sanofi
DEPRESSIVE DISORDERS MARKET: RESEARCH COVERAGE
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the depressive disorders market, focusing on key market segments, including [A] type of depression, [B] type of molecule, [C] type of therapy, [D] route of administration and [E] key geographical regions.
- Market Landscape: A comprehensive evaluation of market landscape, based on several relevant parameters, such as [A] information on drug developer(s), [B] phase of development, [C] type of molecule, [D] type of therapy, [E] type of depression, [F] type of drug class, [G] mechanism of action, [H] dosing frequency and [I] route of administration.
- Discontinued Drug Development Programs Case Study: In-depth assessment of discontinued drugs / trials, focusing on [A] the number of discontinued drug development programs, [B] year of discontinuation, [C] geographical location, [D] phase at which the development program was discontinued, [E] mechanism of action of discontinued drug, [F] disease indication, [G] reason(s) for discontinuation and [H] information on affiliated developer companies.
- Partnerships and Collaborations: A detailed analysis of the deals inked by stakeholders in this domain, based on various parameters, such as [A] year of partnership, [B] type of partnership, [C] area of focus, [D] type of depressive disorder, [E] geography and [F] most active players.
- Fundings and Investments: An in-depth analysis of the fundings received by players in depressive disorders domain, based on relevant parameters, such as [A] number of funding instances, [B] amount invested, [C] type of funding, [D] most active players, [E] most active investors and [F] geography.
- Clinical Trial Analysis: An insightful analysis of clinical trials related to depressive disorders, based on several parameters, such as [A] trial registration year, [B] current trial status, [C] current trial phase, [D] type of depressive disorder, [E] mechanism of action, [F] leading industry and non-industry players with highest number of completed / ongoing trials, [G] regional distribution of clinical trials and [H] enrolled patient population across different geographies.
- Clinical Trial Endpoints Analysis: A detailed analysis of the clinical endpoints in late-stage ongoing and planned studies, for various types of depressive disorders.
- Clinical and Commercial Attractiveness Analysis: A comprehensive assessment of clinical and commercial attractiveness of pipeline molecules based on several parameters, such as [A] size of enrolled patient population, [B] route of administration, [C] therapy type and dosing frequency, [D] target patient population, [E] expected launch date and [F] size of developer company.
- Key Commercialization Strategies: A detailed discussion on the various strategies that can be adopted by the drug developers across key commercialization stages including a timeline representation of the key strategies adopted.
- Digital Therapeutics for Depressive Disorders Case Study: A detailed discussion on the upcoming digital health solutions for the management / treatment of depression, featuring information on the various product development pathways adopted by companies involved in this segment of the market.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
ADDITIONAL BENEFITS
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs for all Analytical Modules in the Report
- 15% Free Content Customization
- Detailed Report Walkthrough Session with Research Team
- Free Updated report if the report is 6-12 months old or older